STUDY: Remdesivir (DisCoVeRy trial)
Does Remdesivir treatment significantly affect mortality, clinical outcomes, or time to improvement in patients hospitalised with severe COVID-19?
Summary: No, it does not.
A short 🧵
Does Remdesivir treatment significantly affect mortality, clinical outcomes, or time to improvement in patients hospitalised with severe COVID-19?
Summary: No, it does not.
A short 🧵
"Remdesivir treatment did not significantly affect mortality, clinical outcomes, or time to improvement in patients hospitalised with severe COVID-19, found a study in The Lancet Infectious Diseases."
"The data included results from the DisCoVeRy trial, which the researchers say is the fifth large randomised controlled trial to include remdesivir thus far. The cohort was recruited from 48 sites in Europe, with 39 sites in France"
"From 22 March 2020 to 21 January 2021, 857 adults were randomly assigned to either standard of care or standard of care plus remdesivir. "
"By day 15, clinical outcomes were not significantly better in the intervention group; odds ratio [OR], 0.98; 95% confidence interval [CI], 0.77 to 1.25).
No significant difference was seen in 28-day mortality (OR, 0.98; 95% CI, 0.57 to 1.52) or time to improvement."
No significant difference was seen in 28-day mortality (OR, 0.98; 95% CI, 0.57 to 1.52) or time to improvement."
"The only significant association was in a subgroup of patients without mechanical ventilation or extracorporeal membrane oxygenation (ECMO), in which those given remdesivir had a 34% (95% CI, 0.47 to 0.91) lower risk of new mechanical ventilation, ECMO, or death."
• • •
Missing some Tweet in this thread? You can try to
force a refresh
